Cargando…

Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance

Direct lytic agents (DLAs) are novel antimicrobial compounds with unique mechanisms of action based on rapid cell wall destabilization and bacteriolysis. DLAs include two classes of purified polypeptides—lysins (peptidoglycan hydrolase enzymes) and amurins (outer membrane targeting peptides). Their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuch, Raymond, Cassino, Cara, Vila-Farres, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928733/ https://www.ncbi.nlm.nih.gov/pubmed/35308352 http://dx.doi.org/10.3389/fmicb.2022.841905

Ejemplares similares

Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus
por: Sauve, Karen, et al.
Publicado: (2017)

711. Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)
por: Anastasiou, Diane, et al.
Publicado: (2019)

Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase
por: Vila-Farres, Xavier, et al.
Publicado: (2023)

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing
por: Oh, Jun T., et al.
Publicado: (2021)

Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection
por: Swift, Steven M., et al.
Publicado: (2021)

1342. Comparison of Lysin CF-301 (Exebacase) Activity Against S. aureus Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates
por: Anastasiou, Diane, et al.
Publicado: (2018)

Rapid Detection of Escherichia coli Antibiotic Susceptibility Using Live/Dead Spectrometry for Lytic Agents
por: Robertson, Julia, et al.
Publicado: (2021)

Bacteriocins in the Era of Antibiotic Resistance: Rising to the Challenge
por: Gradisteanu Pircalabioru, Gratiela, et al.
Publicado: (2021)

In vitro activity of exebacase against methicillin-resistant Staphylococcus aureus biofilms on orthopedic Kirschner wires
por: Karau, Melissa J., et al.
Publicado: (2023)

Antimicrobial Peptides as Anti-Infective Agents in Pre-Post-Antibiotic Era?
por: Rončević, Tomislav, et al.
Publicado: (2019)

Combating Antimicrobial Resistance in the Post-Genomic Era: Rapid Antibiotic Discovery
por: Yang, Yuehan, et al.
Publicado: (2023)

671. Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Xiong, Yan, et al.
Publicado: (2019)

CO-releasing Metal Carbonyl Compounds as Antimicrobial Agents in the Post-antibiotic Era
por: Wareham, Lauren K., et al.
Publicado: (2015)

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis
por: Karau, Melissa, et al.
Publicado: (2022)

712. Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires
por: Karau, Melissa J, et al.
Publicado: (2019)

1264. Assessment of In Vivo Efficacy of CF-296 in addition to Vancomycin (VAN) and Daptomycin (DAP) against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model
por: Asempa, Tomefa E, et al.
Publicado: (2020)

LB3. Exebacase (EXE) Reduced Length of Stay and 30-Day Readmission Rates for US Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia Including Endocarditis Compared with Standard of Care Antibiotics (SoC) Alone in a Phase 2 Study
por: Cassino, Cara, et al.
Publicado: (2019)

Combinatory Therapy Antimicrobial Peptide-Antibiotic to Minimize the Ongoing Rise of Resistance
por: Pizzolato-Cezar, Luis R., et al.
Publicado: (2019)

LB12. Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus bacteremia
por: Cassino, Cara, et al.
Publicado: (2021)

Pre-antibiotic Era Manifestations of Infective Endocarditis in the Era of Modern Antimicrobials
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2020)

Lytic Agents, Cell Permeability, and Monolayer Penetrability
por: Salton, M. R. J.
Publicado: (1968)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity
por: Rabanal, Francesc, et al.
Publicado: (2015)

Rising XDR-Typhoid Fever Cases in Pakistan: Are We Heading Back to the Pre-antibiotic Era?
por: Butt, Muhammad Hammad, et al.
Publicado: (2022)

Polyvalent Phage CoNShP-3 as a Natural Antimicrobial Agent Showing Lytic and Antibiofilm Activities against Antibiotic-Resistant Coagulase-Negative Staphylococci Strains
por: Sofy, Ahmed R., et al.
Publicado: (2020)

The rise of novel antimicrobials
por: Maillard, Jean‐Yves, et al.
Publicado: (2022)

Era of direct acting anti-viral agents for the treatment of hepatitis C
por: Ahmed, Monjur
Publicado: (2018)

Application of Antibiotics/Antimicrobial Agents on Dental Caries
por: Qiu, Wei, et al.
Publicado: (2020)

Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era
por: Totsika, Makrina
Publicado: (2016)

A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides
por: Browne, Katrina, et al.
Publicado: (2020)

Characterization of a Lytic Bacteriophage as an Antimicrobial Agent for Biocontrol of Shiga Toxin-Producing Escherichia coli O145 Strains
por: Liao, Yen-Te, et al.
Publicado: (2019)

Gold Standard Cholera Diagnostics Are Tarnished by Lytic Bacteriophage and Antibiotics
por: Nelson, E. J., et al.
Publicado: (2020)

Evolution of Bacterial Cross-Resistance to Lytic Phages and Albicidin Antibiotic
por: Kortright, Kaitlyn E., et al.
Publicado: (2021)

An Optimized Synthetic-Bioinformatic Natural Product Antibiotic Sterilizes Multidrug-Resistant Acinetobacter baumannii-Infected Wounds
por: Vila-Farres, Xavier, et al.
Publicado: (2018)

Triphenilphosphonium Analogs of Chloramphenicol as Dual-Acting Antimicrobial and Antiproliferating Agents
por: Pavlova, Julia A., et al.
Publicado: (2021)

Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials
por: São-José, Carlos
Publicado: (2018)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Correction: São-José, C. Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials. Antibiotics 2018, 7, 29
por: São-José, Carlos
Publicado: (2018)

Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus
por: Becker, Stephen C., et al.
Publicado: (2016)

Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-Resistant Shigella dysenteriae and Staphylococcus aureus
por: Wang, Feng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jufd87o0j3oq3na2p6o5qssfcl